GATA-4 a potential novel therapeutic target for high-grade meningioma regulates miR-497 a potential novel circulating biomarker for high-grade meningioma

摘要

Meningiomas are the most common primary intracranial tumours. They are classified as grade I, II, and III based on their histopathological features. While most meningiomas can be managed by surgery alone, adjuvant treatment may be required in case of recurrent, or high-grade tumours. To date, chemotherapy has proven ineffective in meningioma patients, reinforcing the need for novel therapeutic targets and molecular biomarkers.